CellCentric, a biotechnology company based in Cambridge, UK, has successfully raised $120 million in Series C funding.

The funding round was led by RA Capital Management and included participation from new investor Forbion, as well as Avego Bioscience Capital and BrightEdge, the American Cancer Society’s venture capital arm.

CellCentric, under the leadership of CEO Will West, is focused on advancing Inobrodib, a novel treatment for cancer patients, particularly those with multiple myeloma. Inobrodib, delivered in the form of an oral capsule, targets p300/CBP to reduce the expression of key cancer drivers like MYC and IRF4. Its favorable safety profile makes it a potential option for patients who cannot access or tolerate other treatments.

Utilization of Funds

• Accelerate the Phase II/III study for heavily pretreated multiple myeloma patients, with the aim of supporting an accelerated approval.
• Support development activities for a Phase III program scheduled to commence in mid-2026.
• Speed up trials starting in Q2 2025, including investigating the combination of inobrodib with bi-specific antibodies and exploring inobrodib in a maintenance setting.

Published by FinSMEs on 19/05/2025